Search | Clinical Trials Finder

Conditions: Heart Transplant Failure, Determination of Death, Outcomes Research, Extracorporeal Membrane Oxygenation
Interventions: Paragonix SherpaPak Cardiac Transport System; Device
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Sickle Cell Disease
Interventions: Briquilimab, Filgrastim, Abatacept, Sirolimus, Cyclophosphamide; Biological · Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 4 Years to 100 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lung Transplant
Interventions: OCS Lung Preservation; Device
Lead sponsor: TransMedics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 8
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 5 more

Conditions: Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum, Pseudomyxoma Peritonei
Interventions: Intestinal, Multivisceral or Modified Multivisceral Transplantation, Alemtuzumab, Tacrolimus, Sirolimus; Procedure · Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cytomegalovirus Infections, Transplant-Related Disorder
Interventions: Letermovir 480 MG [Prevymis]; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infection
Interventions: HIV-infected deceased donor organ; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 18
States / cities: Aurora, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 9 more

Conditions: Lung Transplant
Interventions: XPS™ with Steen Solution™; Device
Lead sponsor: XVIVO Perfusion; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2020
U.S. locations: 18
States / cities: Los Angeles, California • Aurora, Colorado • Gainesville, Florida + 15 more

Conditions: Severe Facial Deformity
Interventions: Facial Allograft Transplantation; Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hematopoietic Stem Cell Transplant, Poor Marrow Graft Function
Interventions: Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion, CliniMACS Cell Selection System; Procedure · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: ESRD, Hepatitis C
Interventions: Kidney transplantation; Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Transplant Sensitization, Panel Reactive Antibody, Sensitization to HLA Antigens
Interventions: Blood Draw; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Idiopathic Pulmonary Fibrosis, Emphysema or COPD
Interventions: CD3/CD19 negative hematopoietic stem cells, Rituximab, Alemtuzumab, Fludarabine, Thiotepa, G-CSF, Hydroxyurea; Biological · Drug
Lead sponsor: Paul Szabolcs; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Awaiting Organ Transplant, Infection in Solid Organ Transplant Recipients
Interventions: Not listed
Lead sponsor: Michael Ison; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Transplant, Kidney Diseases
Interventions: kidney transplant; Procedure
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4
Interventions: Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg, Total Body Irradiation, ATG, Rituximab, Melphalan, CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Kidney Transplant; Drug · Radiation · Device + 1 more
Lead sponsor: Alice Bertaina; Other
Eligibility: 1 Year to 30 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions: Steen Solution™, Conventional Lung Transplant; Device · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Kidney Failure Chronic, Stem Cell Transplant, Stem Cell Transplant Complications, Tolerance, Hematologic Cancer
Interventions: Venetoclax, Hematopoietic Cell Transplantation Conditioning Regimen, Kidney Transplant, Hematopoietic Cell Transplantation; Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Tissue and Organ Procurement, Health Behavior
Interventions: video; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 15 Years and older
Enrollment: 973 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Liver Diseases, Liver Dysfunction, Liver Transplant Disorder, Liver Transplant Rejection
Interventions: LIVERguard; Device
Lead sponsor: Paragonix Technologies; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 7
States / cities: Birmingham, Alabama • Stanford, California • Gainesville, Florida + 4 more

Conditions: Abdominal Wall Defect
Interventions: abdominal wall transplantation, Immunosuppressive Agents; Procedure · Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: EBV-induced Lymphomas, EBV-associated Malignancies, Transplant Patients With EBV Viremia at High Risk of Developing a Recurrent EBV Lymphoma
Interventions: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs); Biological
Lead sponsor: Atara Biotherapeutics; Industry
Eligibility: Not listed
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
Interventions: Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes; Biological
Lead sponsor: Jessie L. Alexander; Other
Eligibility: 1 Month to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Palo Alto, California

Conditions: End-stage Renal Failure, Kidney Graft Rejection
Interventions: Blood drawing for immune monitoring and questionnaires; Other
Lead sponsor: University of Regensburg; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: San Francisco, California • Boston, Massachusetts

Conditions: HIV Infection, Liver Transplant
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Search by objective public record fields.

Evaluation of Safety and Effectiveness of The SherpaPak in Donation After Circulatory Death Heart Transplantation

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

International EXPAND Lung Pivotal Trial

Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients

Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs

Face Transplantation for Treatment of Severe Facial Deformity

T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation

Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR

An In-vitro Standardization of B Cell Elispot Assays

Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure

Cell Mediated Immunity With Risk of Cytomegalovirus (CMV) in Solid Organ Transplant Recipients

Donor Outcomes Following Hand-Assisted and Robotic Living Donor Nephrectomy: a Retrospective Review

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability

Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation

Community Trial to Enhance Organ Donation

Global Utilization And Registry Database for Improved preservAtion of doNor Livers

Vascularized Composite Allotransplantation for Treatment of Abdominal Wall Defects

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Reference Group Trial for The ONE Study

Expanding HOPE Liver